Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- USD | -.--% | -.--% | -.--% |
Business Summary
Sales per Business
HKD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Biopharmaceutical
100.0
%
| 3,738 | 100.0 % | 5,961 | 100.0 % | +59.47% |
Sales per region
HKD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
China
89.2
%
| 3,303 | 88.4 % | 5,316 | 89.2 % | +60.92% |
North America
5.8
%
| 169 | 4.5 % | 348 | 5.8 % | +106.21% |
Asia Pacific (excluding China)
3.6
%
| 208 | 5.6 % | 214 | 3.6 % | +3.00% |
Europe
1.0
%
| 58 | 1.6 % | 62 | 1.0 % | +6.83% |
South America
0.4
%
| - | - | 21 | 0.4 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Wei Dong Jiang
FOU | Founder | - | 09-11-30 |
Jun Zhu
CEO | Chief Executive Officer | 46 | 21-11-29 |
Wei Huang
PSD | President | 56 | 20-09-30 |
Wen Jie Zhang
CHM | Chairman | 57 | 19-02-28 |
Simon Hsu
CTO | Chief Tech/Sci/R&D Officer | - | - |
Miao Jie Chen
CMP | Compliance Officer | 41 | - |
Ye Xing Yuan
BRD | Director/Board Member | 39 | 22-12-31 |
Jin Li
LAW | General Counsel | - | 21-09-12 |
Jing Li
PRN | Corporate Officer/Principal | - | - |
Ping Cao
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Qi Yu Chen
BRD | Director/Board Member | 52 | 13-01-14 |
Tak Young So
BRD | Director/Board Member | 54 | 19-09-01 |
Xiao Hui Guan
BRD | Director/Board Member | 53 | 18-12-23 |
Yi Fang Wu
BRD | Director/Board Member | 54 | 15-06-11 |
De Yong Wen
BRD | Director/Board Member | 52 | 22-07-27 |
Lik Yuen Chan
BRD | Director/Board Member | 55 | - |
Guo Ping Zhao
BRD | Director/Board Member | 75 | 19-09-01 |
Rong Li Feng
CHM | Chairman | 49 | 20-04-20 |
De Li Kong
BRD | Director/Board Member | 50 | 16-07-31 |
Xing Li Wang
BRD | Director/Board Member | 61 | 23-08-27 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 380,066,312 | 0 | 0 | 15.03 % |
Stock B | 1 | 163,428,541 | 81,687,447 ( 49.98 %) | 0 |
Company contact information
Shanghai Henlius Biotech, Inc.
Innov Tower 1801 Hongmei Road, Xuhui District
200233, Shanghai
+
http://www.henlius.comSector
Sales per region
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-2.32% | 92.59B | |
+3.68% | 41.43B | |
-11.44% | 33.49B | |
-19.22% | 14.62B | |
-8.95% | 12.77B | |
-11.34% | 11.58B | |
-43.53% | 11.35B | |
+3.75% | 8.97B | |
-6.32% | 8.3B |
- Stock Market
- Equities
- 2696 Stock
- SGBCF Stock
- Company Shanghai Henlius Biotech, Inc.